Truist raised the firm’s price target on AbbVie to $215 from $210 and keeps a Buy rating on the shares. The firm is adjusting the In-Process Research and Development – IPR&D – expense in its model ahead of the company’s Q3 results, the analyst tells investors in a research note. Truist is also incorporating tavapadon into its model with assumed $1B in peak sales, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: